Masafumi Shimoda1, Yoshito Tomimaru1, Kevin P Charpentier2, Howard Safran3, Rolf I Carlson1, Jack Wands4. 1. Liver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA. 2. The Department of Surgery, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA. 3. The Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA. 4. Liver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA; The Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: jack_wands_md@brown.edu.
Abstract
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has a poor survival rate due to recurrent intrahepatic metastases and lack of effective adjuvant therapy. Aspartate-β-hydroxylase (ASPH) is an attractive cellular target since it is a highly conserved transmembrane protein overexpressed in both murine and human HCC tumors, and promotes a malignant phenotype as characterized by enhanced tumor cell migration and invasion. METHODS: Dendritic cells (DCs), expanded and isolated from the spleen, were incubated with a cytokine cocktail to optimize IL-12 secretion and co-stimulatory molecule expression, then subsequently loaded with ASPH protein for immunization. Mice were injected with syngeneic BNL HCC tumor cells followed by subcutaneous inoculation with 5-10×10(5) ASPH loaded DCs using a prophylactic and therapeutic experimental approach. Tumor infiltrating lymphocytes (TILs) were characterized, and their role in producing anti-tumor effects determined. The immunogenicity of ASPH protein with respect to activating antigen specific CD4+ T cells derived from human peripheral blood mononuclear cells (PBMCs) was also explored. RESULTS: We found that immunotherapy with ASPH-loaded DCs suppressed and delayed established HCC and tumor growth when administered prophylactically. Ex-vivo re-stimulation experiments and in vivo depletion studies demonstrated that both CD4+ and CD8+ cells contributed to anti-tumor effects. Using PBMCs derived from healthy volunteers and HCC patients, we showed that ASPH stimulation led to significant development of antigen-specific CD4+ T-cells. CONCLUSIONS: Immunization with ASPH-loaded DCs has substantial anti-tumor effects which could reduce the risk of HCC recurrence. Copyright Â
BACKGROUND & AIMS:Hepatocellular carcinoma (HCC) has a poor survival rate due to recurrent intrahepatic metastases and lack of effective adjuvant therapy. Aspartate-β-hydroxylase (ASPH) is an attractive cellular target since it is a highly conserved transmembrane protein overexpressed in both murine and humanHCC tumors, and promotes a malignant phenotype as characterized by enhanced tumor cell migration and invasion. METHODS: Dendritic cells (DCs), expanded and isolated from the spleen, were incubated with a cytokine cocktail to optimize IL-12 secretion and co-stimulatory molecule expression, then subsequently loaded with ASPH protein for immunization. Mice were injected with syngeneic BNL HCC tumor cells followed by subcutaneous inoculation with 5-10×10(5) ASPH loaded DCs using a prophylactic and therapeutic experimental approach. Tumor infiltrating lymphocytes (TILs) were characterized, and their role in producing anti-tumor effects determined. The immunogenicity of ASPH protein with respect to activating antigen specific CD4+ T cells derived from human peripheral blood mononuclear cells (PBMCs) was also explored. RESULTS: We found that immunotherapy with ASPH-loaded DCs suppressed and delayed established HCC and tumor growth when administered prophylactically. Ex-vivo re-stimulation experiments and in vivo depletion studies demonstrated that both CD4+ and CD8+ cells contributed to anti-tumor effects. Using PBMCs derived from healthy volunteers and HCCpatients, we showed that ASPH stimulation led to significant development of antigen-specific CD4+ T-cells. CONCLUSIONS: Immunization with ASPH-loaded DCs has substantial anti-tumor effects which could reduce the risk of HCC recurrence. Copyright Â
Authors: Douglas J Schwartzentruber; David H Lawson; Jon M Richards; Robert M Conry; Donald M Miller; Jonathan Treisman; Fawaz Gailani; Lee Riley; Kevin Conlon; Barbara Pockaj; Kari L Kendra; Richard L White; Rene Gonzalez; Timothy M Kuzel; Brendan Curti; Phillip D Leming; Eric D Whitman; Jai Balkissoon; Douglas S Reintgen; Howard Kaufman; Francesco M Marincola; Maria J Merino; Steven A Rosenberg; Peter Choyke; Don Vena; Patrick Hwu Journal: N Engl J Med Date: 2011-06-02 Impact factor: 91.245
Authors: Geoffrey Y Ku; Jianda Yuan; David B Page; Sebastian E A Schroeder; Katherine S Panageas; Richard D Carvajal; Paul B Chapman; Gary K Schwartz; James P Allison; Jedd D Wolchok Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: Katsuya Nagaoka; Xuewei Bai; Kosuke Ogawa; Xiaoqun Dong; Songhua Zhang; Yanmei Zhou; Rolf I Carlson; Zhi-Gang Jiang; Steve Fuller; Michael S Lebowitz; Hossein Ghanbari; Jack R Wands Journal: Cancer Lett Date: 2019-02-12 Impact factor: 8.679
Authors: Yoshito Tomimaru; Sasmita Mishra; Howard Safran; Kevin P Charpentier; William Martin; Anne S De Groot; Stephen H Gregory; Jack R Wands Journal: Vaccine Date: 2015-01-25 Impact factor: 3.641